Literature DB >> 27163514

Left Atrial Sphericity Index Predicts Early Recurrence of Atrial Fibrillation After Direct-Current Cardioversion: An Echocardiographic Study.

Armin Osmanagic1, Sören Möller2, Azra Osmanagic3, Hussam M Sheta1, Kristina H Vinther1, Kenneth Egstrup1.   

Abstract

BACKGROUND: Attempts to achieve rhythm control using direct-current cardioversion (DCC) are common in those with persistent atrial fibrillation (AF). Although often successful, AF recurs within 1 month in as many as 57% of patients. The aim of this study was to assess whether a baseline left atrial sphericity index (LASI) acquired by 2-dimensional transthoracic echocardiography (TTE) could be used as a predictor of AF recurrence after successful DCC. HYPOTHESIS: A baselline LASI assessed by 2D TTE can predict AF recurrence after successful DCC in patients with persistent AF.
METHODS: A total of 124 consecutive patients with persistent AF lasting <120 days underwent successful DCC. Other than β-blockers, no other antiarrhythmic treatment was administered. Prior to DCC, all patients underwent thorough TTE, and LASI was calculated as the fraction of the left atrial width/length of the largest possible left atrial volume in a 4-chamber view. The primary outcome was a TTE-estimated baseline LASI as a predictor of AF recurrence after successful DCC for persistent AF.
RESULTS: Anatomically, a more spherical shape of the left atrium (LASI >0.9) proved to be a strong and independent predictor of AF recurrence, with an odds ratio between 4.1 (95% confidence interval: 1.6-11.9, P = 0.005) and 7.6 (95% confidence interval: 3.3-19.7; P = 7.2 × 10(-6) ). The receiver operating characteristic curve indicated good power for distinguishing between recurring and nonrecurring AF, and we chose a cutoff of 0.9 because high specificity was a priority for clinical reasons.
CONCLUSIONS: In conclusion, baseline LASI >0.9 was associated with significantly greater AF recurrence throughout the 12-month follow-up period.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27163514      PMCID: PMC6490717          DOI: 10.1002/clc.22545

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

1.  The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion.

Authors:  Mehrnoush Toufan; Babak Kazemi; Negin Molazadeh
Journal:  J Cardiovasc Thorac Res       Date:  2017-03-18

2.  Clinical significance of left atrial geometry in dilated cardiomyopathy patients: A cardiovascular magnetic resonance study.

Authors:  Mayu Yazaki; Takeru Nabeta; Takayuki Inomata; Kenji Maemura; Takumi Oki; Teppei Fujita; Yuki Ikeda; Shunsuke Ishii; Takashi Naruke; Yusuke Inoue; Junya Ako
Journal:  Clin Cardiol       Date:  2020-12-09       Impact factor: 2.882

3.  Revisiting left atrial volumetry by magnetic resonance imaging: the role of atrial shape and 3D angle between left ventricular and left atrial axis.

Authors:  Jouni K Kuusisto; Pauli A K Pöyhönen; Jani Pirinen; Lauri J Lehmonen; Heli P Räty; Nicolas Martinez-Majander; Jukka Putaala; Juha Sinisalo; Vesa Järvinen
Journal:  BMC Med Imaging       Date:  2021-11-09       Impact factor: 1.930

4.  3D electroanatomical mapping is less sensitive to atrial remodeling in estimation of true left atrial volume than echocardiography.

Authors:  Zdenka Fingrova; Josef Marek; Stepan Havranek; Lukas Lambert; Petr Kuchynka; Ales Linhart
Journal:  BMC Med Imaging       Date:  2018-09-18       Impact factor: 1.930

5.  The application of novel segmentation software to create left atrial geometry for atrial fibrillation ablation: The implication of spatial resolution.

Authors:  Chye-Gen Chin; Fa-Po Chung; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Ta-Chuan Tuan; Tze-Fan Chao; Jo-Nan Liao; Chin-Yu Lin; Ting-Yung Chang; Cheng-I Wu; Chih-Min Liu; Jennifer Jeanne B Vicera; Chun-Chao Chen; Chieh-Mao Chuang; Yi-Jen Chen; Ming-Hsiung Hsieh; Shih-Ann Chen
Journal:  J Chin Med Assoc       Date:  2020-09       Impact factor: 3.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.